Spots Global Cancer Trial Database for Metformin Prostate Cancer Adjuvant Trial

The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.

Trial Identification

Brief Title: Metformin Prostate Cancer Adjuvant Trial

Official Title: Phase II Clinical Study of Effect of Metformin on Prostate Specific Antigen Doubling Time

Study ID: NCT02176161

Conditions

Prostate Cancer

Prostate Cancer Recurrent

Interventions

Metformin Hydrochloride Extended Release 750mg

Study Description

Brief Summary: This is a Phase II clinical study to determine if Metformin can increase Prostate Specific Antigen (PSA) doubling time for patients with Prostate Cancer who have failed primary treatment with radiation, or surgical patients that are at high risk for recurrence based on surgical pathology. Men with confirmed prostate cancer and rising serum PSA levels will receive Metformin and will be monitored for PSA response and disease progression.

Detailed Description: Prostate cancer patients who have received treatment with radiation therapy or surgery, who have indicators of high-risk disease will be administered 750mg Metformin Extended Release twice per day for a period of 9 months. Metformin is an FDA-approved drug that is prescribed to treat high blood sugar levels in patients with Type 2 Diabetes. To track prostate cancer response in study participants, investigators will obtain prostate specific antigen (PSA) levels every three months for the duration of the trial.